San Antonio, Texas
March 21-26, 2026
Booth #512
Connect with Caris Life Sciences at USCAP 2026
Caris Life Sciences® is proud to join the USCAP Annual Meeting in San Antonio, Texas. Meet our team to discover the latest innovations in precision medicine and learn how our products and services are leading the molecular revolution. Explore our Pathology Program to learn how we support pathologists with advanced molecular insights and clinical decision support.
USCAP 2026 Oral Presentation
BCORL1::CREBBP Fusions Characterize an Aggressive Frequently Ossifying Bone and Soft Tissue Sarcoma with Predilection for the Clavicular Bone
Oral #808
March 24, 2026
2:00 PM – 2:15 PM CDT
USCAP 2026 Poster Presentations
Landscape and Molecular/Clinical Correlates of Pathogenic Gene Fusions in Melanoma: A Comprehensive Molecular Profiling Study
Poster #48
March 23, 2026
Time: 1:00 PM – 4:30 PM CDT
Comprehensive Analysis of Adult NTRK-Rearranged Sarcomas: Clinical, Pathologic, and Genomic Correlates
Poster #69
March 23, 2026
Time: 1:00 PM – 4:30 PM CDT
Secondary Genetic Alterations in Extraskeletal Myxoid Chondrosarcoma: Beyond NR4A3
Poster #70
March 23, 2026
Time: 1:00 PM – 4:30 PM CDT
Interplay of Programmed Death-Ligand 1 (PD-L1) Expression in Gastrointestinal Stromal Tumor (GIST): Correlation with Clinicopathologic Features, Comprehensive Genomic Profile, and Disease Outcome.
Poster #63
March 24, 2026
Time: 1:00 PM – 4:30 PM CDT
Schedule a Meeting
Products at a glance
Caris Assure
Whole Exome and Whole Transcriptome Sequencing from blood. This revolutionary, pan-cancer assay utilizes a novel circulating Nucleic Acid Sequencing (cNAS) approach. With deep molecular insights from a minimally invasive blood sample, Caris Assure™ delivers uncompromising reliability and performance to inform personalized treatment decisions to help improve patient outcomes.
MI Cancer Seek
MI Cancer Seek® is the first and only simultaneous Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS)-based assay with FDA-approved CDx indications for molecular profiling of solid tumors. MI Cancer Seek is available for adult and pediatric (ages 1-22) patients.
Caris Molecular AI
With one of the largest, multi-modal databases of combined molecular and clinical outcomes data in the world, Caris applies highly sophisticated AI bioinformatics and machine learning capabilities on this massive database to create novel, clinically relevant solutions to classify cancer at the molecular level and predict patient response in ways never before possible.
Complete Molecular Intelligence Report
The Caris Molecular Profiling Report delivers high impact results, including potentially relevant, actionable clinical information, in an easy-to-interpret format. Every report includes access to the MI Portal and the Clinical Trials Connector™, which matches each patient’s unique biomarker expression profile to open, pertinent clinical trial opportunities.
Discover
More
Personalized Treatment Starts Here
Understanding cancer at the molecular level can lead to better treatment options. Caris molecular profiling includes whole exome and whole transcriptome sequencing of tissue and blood, plus protein analysis and other testing options for tissue specimens. Paired with molecular AI tools, Caris comprehensive molecular profiling is focused on helping cancer patients today and tomorrow.
Expert Scientific and Clinical Support
Caris’ healthcare provider services help put precision medicine into practice. Deep molecular insights enable physicians to navigate among therapies with potential benefit, identify therapies that may not have been considered, determine drugs unlikely to provide benefit (avoiding unnecessary toxicities and costs) and match patients to clinical trials.